17 MAR 2016

MEMORANDUM FOR SGVT
ATTN: CAPT JESSICA S PABON

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled **Evaluating the Benefits of Utilizing Dronabinol in the Treatment of Chronic Pain Patients: A Retrospective Cohort Study** presented at **Alcalde Southwest Leadership, Frisco, Texas 19-21 April 2016** with MDWI 41-108, and has been assigned local file #16111.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

[Signature]

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

*Partners in a high-performance health system, dedicated to excellence in global care*
PROCESSING OF PROFESSIONAL MEDICAL RESEARCH PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS

1. The author must complete page two of the 59 MDW Form 3039 (this form):
   a) In Section 2, add the funding source for your study (e.g., 59 MDW CRD Graduate Health Sciences Education (GHSC) [SG5 O&M], SG5 R&D, Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH: Congressionally Directed Medical Research Program (CDMRP); Grants; etc.)

2. Print your name, rank/grade, sign and date the form in the author's signature block or use electronic signature.

3. Attach a copy of the 59th MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box of the 59 MDW Form 3039.

4. Attach a copy of your abstract, paper, poster and other supporting documentation.

5. Save and forward, via email, the processing form and all supporting documentation to your Unit Commander, Program Director or immediate supervisor for review/approval.

6. On page 2, have either your Unit Commander, Program Director or immediate supervisor:
   a) Print their name, rank/grade/title, sign and date the form in the approving authority's signature block or use electronic signature.

7. Contact the 59th CRD/Publications and Presentations Section at (292-7141) for instructions for submitting the request form.

8. The 59th CRD/Publications and Presentations Section will route the request form to clinical investigations and public affairs and forward you a final letter of approval or disapproval.

9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on the 59 MDW Form 3039. [NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.]

10. If your manuscript is accepted for scientific publication, please contact the 59th CRD/Publications and Presentations Section (292-7141). This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDW 41-108, Presentation and Publication of Medical and Technical Papers for additional information.

   NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

   "The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components."

   NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

   "The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DoDI 3216.02_AFI 40-402, Protection of Human Subjects in Biomedical and Behavioral Research."

   NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP, The Care and Use of Laboratory Animals in DoD Programs:

   "The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."
PROCESSING OF PROFESSIONAL MEDICAL RESEARCH PUBLICATIONS/PRESENTATIONS

TO: Clinical Research Division/SGVU (59 MDW/SGVU)
FROM: Author's Name, Rank, Grade, Office Symbol
Protocel, Jessica S., Capt, O3, SGVPI

PROTOCOL NUMBER: C2016.033d

PROTOCOL TITLE - [NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.]
Evaluating the Benefits of Utilizing Dronabinol in the Treatment of Chronic Pain Patients: A Retrospective Cohort Study

1. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED
Evaluating the Benefits of Utilizing Dronabinol in the Treatment of Chronic Pain Patients: A Retrospective Cohort Study

2. FUNDING RECEIVED FOR THIS STUDY? ☑ YES ☐ NO
FUNDING SOURCE:

3. IS THIS MATERIAL CLASSIFIED? ☐ YES ☑ NO

4. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? ☐ YES ☑ NO
NOTE: If the answer is "YES" then attach a copy to the Agreement to the Publications/Presentations Request Form.

5. MATERIAL IS FOR (Check appropriate box or boxes for approval with this request.)
☐ PUBLICATION/JOURNAL (List intended publication/journal)
☐ PUBLICATION ABSTRACT (List intended journal)
☒ POSTER (To be demonstrated at meeting/Name of Meeting, City, State, and Date of Meeting)
Alcalde Southwest Leadership, Frisco, Texas 19-21 April 2016
☐ PLATFORM PRESENTATION (At civilian institutions/Name of Meeting, State, Date of Meeting)
☐ OTHER (Describe: Name of Meeting, City, State, and Date of Meeting)

6. WHAT IS THE EXPECTED DATE YOUR PRESENTATION/PUBLICATION WILL BE SUBMITTED TO THE DEFENSE TECHNICAL INFORMATION CENTER (DTIC)?
08Apr16

7. WHO IS THE PRIMARY 59 MDW POINT OF CONTACT? (Last, First, Mt.) (Include email)
Pabon, Jessica S. Jessica.S.Pabon.mil@mail.mil
DUTY PHONE/PAGER No.
210-513-2741

AUTHORSHIP AND CO-AUTHOR(S) (List in the order they will appear in the manuscript)

<table>
<thead>
<tr>
<th>LAST NAME, FIRST NAME AND MI.</th>
<th>GRADE/RANK</th>
<th>SQUADRON/GROUP/INSTITUTION</th>
<th>INSTITUTION (If not 59 MDW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Primary/corresponding author</td>
<td>Capt Jessica S. Pabon, USAF, BSC</td>
<td>O3/Capt</td>
<td>959CPS/59MDW/SGVPI</td>
</tr>
<tr>
<td>b. Dr. Emily Davies, Pharm.D</td>
<td>Civ</td>
<td></td>
<td>BAMC</td>
</tr>
<tr>
<td>c. Dr. Justin Boge, D.O., M.S.</td>
<td>Civ</td>
<td></td>
<td>BAMC</td>
</tr>
<tr>
<td>d. Dr. Benjamin Keizer, Ph.D</td>
<td>GS-13</td>
<td></td>
<td>BAMC</td>
</tr>
<tr>
<td>e.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>f.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>g.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401 IP AND 59 MDW 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.

AUTHOR'S PRINTED NAME/RANK/GRADE
Pabon, Jessica S./Capt/O3

APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE
Fenzl, Heather, Major, USAF, BSC

AUTHOR'S SIGNATURE
PABON,JESSICA,SELENA.1017943
630

APPROVING AUTHORITY'S SIGNATURE
FENZL,HEATHER,WINFREE.126393
8152

DATE
01Mar16

DATE
Mar 4, 2016

59 MDW Form 3039 (DATE) Supersedes 59 MDW Form 3039, 20131018 Page 2 of 3
### 1st INDORSEMENT (SGVU Use Only)

- **TO:** Clinical Research Division  
  (59 MDW/SGVU)  
  (Contact 292-7141 for email instructions)
- **DATE RECEIVED:** 3/7/2016
- **ASSIGNED PROCESSING REQUEST FILE NUMBER:** 16111
- **DATE REVIEWED:** 7 Mar 2016
- **DATE FORWARDED TO PA:**
- **AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES:**  
  [ ] NO  [x] YES  If yes give date: 7 Mar 2016  [ ] N/A

### 6. COMMENTS

- [x] APPROVED  [ ] DISAPPROVED

The article is approved.

### 2nd INDORSEMENT (PA Use Only)

- **TO:** 59 MDW OFFICE OF PUBLIC AFFAIRS  
  (PA)
- **DATE RECEIVED:** Mar 15, 2016
- **DATE FORWARDED TO 59 MDW/SGVU:** Mar 16, 2016
- **COMMENTS:**  
  [x] APPROVED (In compliance with security and policy review directives.)  [ ] DISAPPROVED

### 3rd INDORSEMENT (SGVU Use Only)

- **TO:** 59 MDW/SGVU
- **DATE RECEIVED:**
- **SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL:**  
  [ ] YES  [ ] NO  [ ] Could not be reached  [ ] Left message
- **DATE WRITTEN NOTICE OF APPROVAL AND CLEARANCE MAILED TO AUTHOR:**
- **COMMENTS:**  
  [ ] APPROVED  [x] DISAPPROVED

### Printed Name, Rank/Grade, Title of Reviewer

- **Christopher Carwile, Tsgt/E-6, NCOIC, PA**  
  (Digital signature by CARWILE.CHRISTOPHER.S.1280477229)

### Signature of Reviewer

- **CALCOTE.ROCKY.D.1178245844**  
  (Digital signature by CALCOTE.ROCKY.D.1178245844)

---

59 MDW Form 3039 (DATE) Supersedes 59 MDW Form 3039, 20131018  
Page 3 of 3
EVALUATING THE BENEFITS OF UTILIZING DRONABINOL IN THE TREATMENT OF CHRONIC PAIN PATIENTS: A RETROSPECTIVE COHORT STUDY. Jessica S. Pabon, Emily E. Davies, Justin Boge, and Benjamin M. Keizer. San Antonio Military Medical Center (SAMMC), Fort Sam Houston, TX.

PURPOSE: To evaluate change in Oral Morphine Dose Equivalence (OMDE) in patients prescribed dronabinol for the treatment of chronic pain. Chronic opioid therapy (COT), although controversial, has been the mainstay treatment for most chronic pain (CP) diagnoses. Over time, increased research evidence has shown an escalated risk of serious harm associated with long term use of COT can outweigh benefits.

METHODS: Retrospective data was collected from 76 patients utilizing two Electronic Health Record chart review systems during the time frame of Jan 2015-Dec 2015 being treated at Brooke Army Medical Center Pain Management Clinic and the Moreno Primary Warrior Transition Unit (WTU) Clinic. The therapeutic differences of OMDE before and after dronabinol treatment were measured utilizing the daily narcotic doses prescribed, the Defense Veteran Pain Rating Scale (DVPRS) scores, Chronic Opioid Misuse Measurement (COMM) score, and the Post-traumatic Checklist (PCL) score. Additionally, an Analysis of Variance (ANOVA) will compare the patients’ pain types (somatic, visceral, and neuropathic) in accordance to the objective measures and a logistic regression will account for various confounders.

RESULTS: Pending

CONCLUSION: Pending

*The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components.
MEMORANDUM FOR 59 MDW
ATTN: CAPT JESSICA S. PABON

FROM: 502 ISG/JA

SUBJECT: Ethics Review for Presentation Approval Request (Pabon)

1. Capt Pabon submitted a request for a legal review of a poster titled “Evaluating the Benefits of Utilizing Dronabinol in the Treatment of Chronic Pain Patients: A Retrospective Cohort Study.” The author plans to present this research as a poster at the Alcalde Southwest Leadership Conference in Frisco, Texas on 19-21 April 2016. This legal review is limited to the ethics issues regarding the presentation. The abstract contains the required disclaimer discussed below. The disclaimer must also be included on the poster. The abstract must also be submitted for Public Affairs approval. There are no conflict of interest issues with presenting this research at this professional society meeting.

2. FACTS: Capt Pabon plans to present her poster titled “Evaluating the Benefits of Utilizing Dronabinol in the Treatment of Chronic Pain Patients: A Retrospective Cohort Study” at the Alcalde Southwest Leadership Conference in Frisco, Texas on 19-21 April 2016.

3. LAWS AND REGULATIONS: DoD 5500.07-R, Joint Ethics Regulation (JER), section 3-305 lays out rules governing “Teaching, Speaking and Writing.” If the presentation will “deal in significant part with any ongoing or announced policy, program or operation” of the Air Force, the presenter is required to include a disclaimer that states the "views presented are those of the speaker or author and do not necessarily represent the views of DoD or its Components."

4. ANALYSIS: The presentation does not "deal in significant part with any ongoing or announced policy, program or operation” of the Air Force, however, the abstract does address research done as part of the author’s military medical practice. Additionally, the presenter’s affiliation with the military will presumably be included as part of the presentation. The author has included the required disclaimer that the views presented are those of the authors and do not necessarily represent the views of DoD or its Components on the slide presentation. The disclaimer must be included on the poster. There are no apparent conflicts of interest that would prohibit the presentation.

5. CONCLUSIONS: The abstract presented for review included the disclaimer required by the JER. The disclaimer must be included on the poster.
6. If you have any questions, please call me at 210-671-5771.

[Signature]

VERNISHA N. FOSTER, Captain, USAF
Assistant Staff Judge Advocate

I concur.

[Signature]

MARK E. COON, Major, USAF
Acting Chief, Civil Law